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Not all asthmatic patients adequately respond to current available treatments, such as 
inhaled corticosteroids or omalizumab®. New treatments will aim to target the bronchial 
epithelium–immune response interaction using different pathways. HLA-G is involved 
in immunomodulation and may promote epithelial cell differentiation and proliferation. 
HLA-G protein has several isoforms generated by alternative splicing that might have 
differential functionalities. HLA-G protein expression and genetic polymorphisms have 
been reported to be associated with asthma. Our hypothesis is that bronchial epithelium 
from asthmatic patients displays less functional HLA-G isoforms. HLA-G transcriptional 
isoforms were quantified by real-time PCR in human bronchial epithelium cells (HBEC) 
grown in air–liquid interface culture obtained from five healthy controls (HC), seven 
patients with mild asthma (MA), and seven patients with severe asthma (SA). They 
were re-differentiated, and IL-13 exposure was used as a proxy for a pro-inflammatory 
cytokine. HLA-G protein expression was assessed by western blot analysis. HLA-G 
allele was typed by direct sequencing. Our results showed that both MA and SA display 
less functional HLA-G isoforms than HC (p < 0.05); in vitro HBEC re-differentiation from 
SA displays a particular isoform expression profile compared to MA and HC (p = 0.03); 
HLA-G*01:06 frequency in MA and SA was significantly higher than in the healthy 
population (p = 0.03 and p < 0.001, respectively); and IL-13 exposure had no impact on 
HLA-G expression. Our results support that an impaired expression of HLA-G isoforms 
in asthmatic patients could contribute to the loss of inflammation control and epithelium 
structural remodeling. Therefore, HLA-G might be an interesting alternative target for 
asthmatic patients not adequately responding to current drugs.
Keywords: asthma, epithelium, hla-g, immunomodulation, isoforms
Abbreviations: PBMC, peripheral blood mononuclear cells; ALI, air–liquid interface; FEV1, forced expiratory volume in 1 s; 
GERD, gastroesophageal reflux disease; HBEC, human bronchial epithelial cells; ICS, inhaled corticosteroid; LAβ2, long-acting 
β2 agonist; SAβ2, short acting β2 agonist; OCS, oral corticosteroid.
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inTrODUcTiOn
Asthma affects almost 300 million people worldwide and is 
related to a chronic inflammation of the airways. It groups various 
phenotypes which can be classified according to clinical severity, 
age of onset, and different immune responses, i.e., T2-associated 
and non-T2 asthma (1). T2-associated asthma is characterized by 
the release of interleukins IL-13 and IL-5, promoting eosinophilic 
infiltration, pro-inflammatory loops, epithelial cell proliferation, 
goblet-cell metaplasia, and ciliary beating alterations (1). Non-T2 
asthma is more often associated with neutrophilic inflammation 
and a mixed T1 and T17 cytokine milieu (2).
The bronchial epithelium is abnormal in asthma, with struc-
tural changes and thickening of the sub-epithelial layer (3), and 
its function is characterized by an exaggerated release of various 
cytokines, including TSLP, IL-33, and IL-25, as well as impaired 
inflammation resolution (4). Human bronchial epithelium 
cells (HBEC), in direct contact with the external environment, 
are key sensors of viruses, allergens, or pollutants through 
pathogen-associated molecular patterns (PAMPs), NOD2, and 
TLR [for review, see Ref. (5)]. HBEC can initiate and perpetu-
ate immune responses by recruiting effector cells through the 
release of mediators (2). HBEC from severe asthma patients 
secrete higher levels of IL-8, a chemoattractant for neutrophils, 
and reduced levels of lipoxins, mediators which normally resolve 
inflammation (6).
Therapeutics based on the association of corticosteroids, 
leukotriene receptor antagonists, and long-acting beta agonists 
are efficient in about 80% of asthmatic patients. Immune-based 
therapies have been developed to specifically reduce T2 immune 
cell activity either by blocking the pro-inflammatory cytokine 
loop (using, for example, anti-IL-5, IL-13, or IL-4, monoclonal 
antibodies) or by blocking activating-receptor fixation (using, for 
example, anti-IgE monoclonal antibody preventing IgE fixation to 
FcεRI, omalizumab®), significantly increasing various outcomes, 
including exacerbation rates, and improving pulmonary function 
tests in patients with T2-associated asthma not responding to 
inhaled corticosteroid treatment (ICS) (7).
Despite these approaches, there is no drug at present which 
interferes with the natural history of the disease and can be 
called a disease modifier. Thus, efforts are made to develop 
new therapeutic strategies, and in this regard, the interaction 
between the bronchial epithelium and immune response is gain-
ing interest (8, 9).
Besides their role in promoting inflammation, HBEC also 
express the immunotolerant HLA-G molecule, extensively docu-
mented for its involvement in immune scenarios, such as solid 
tumors, viral infections, and autoimmune diseases [for review, 
see Ref. (10)].
In asthma, HLA-G expression was found to be increased in 
lung tissues. Broncho alveolar lavage fluid and plasma HLA-G 
levels were higher in asthmatic individuals than in healthy vol-
unteers (11–13). Interestingly, White et al. reported that HLA-G 
expression in healthy HBEC was independent from T2-related 
cytokines IL-4, IL-5, or IL-13 (14).
HLA-G inhibits NK- and cytotoxic T lymphocyte-mediated 
activity as well as B cell activation via their inhibitory receptor 
(ILT-2, -4 and KIR2DL4). This non-classical HLA class I molecule 
also acts indirectly on immune control as HLA-E preferentially 
loads its signal peptide (15).
HLA-G is involved in epithelial cell differentiation: its expres-
sion increases proliferation and differentiation properties of 
amnion epithelial cells (16), and it is upregulated in fetal lungs 
suggesting a role in lung development (17).
Functional analysis of HLA-G is challenging because of its 
many levels of polymorphism: dimerization, association with 
β2-microglobulin, and alternative splicing (18). Primary HLA-G 
mRNA splicing generates both membrane-bound (HLA-G1–4) 
and soluble (HLA-G5–7) isoforms (18), and membrane-bound 
isoforms can also be shed via proteolytic cleavage by matrix 
metalloproteinase-2 (19). The HLA-G1 and -G5 isoforms display 
a similar structure to HLA class Ia molecules (α1, α2, and α3 
domains), whereas HLA-G2 and -G6 are composed of α1 and 
α3 domains, -G3 and -G7 contain an α1 domain, and -G4 is 
composed of α1 and α2 domains (18). These truncated isoforms 
appear to be differently processed, as HLA-G2, -G3, and -G4 are 
sensitive to endoglycosidase H, suggesting a non-involvement of 
the Golgi apparatus, conversely to HLA-G1 and classical HLA 
class I (20).
Alpha1 and α3 domains have been, respectively, described 
to bind the KIR2DL4 inhibitory receptor and ILT-2 and -4 (21, 
22). Thus, differential functional activity can be expected for 
these isoforms. Both HLA-G1 and -G5 isoforms reduce NK cell 
cytotoxicity with an additive effect (23). Two studies concluded 
functional activity for HLA-G2, -G4, and -G6 (20), whereas 
conflicting results were published concerning HLA-G3 (20, 
24). A supplementary level of splicing is generated due to the 
14  bp insertion polymorphism in exon 8 (ex8); this insertion 
introduces an additional splice site which removes the first 92 bp 
of exon 8, generating a more stable transcript and a protein that 
inhibits NK cytotoxicity more efficiently (25, 26).
Several studies focused on HLA-G isoform expression 
supported a differential impact on their immunomodulation 
and differentiation properties. In pregnancy, HLA-G5 mRNA 
and protein was significantly lower in abortion-threatened 
women, whereas HLA-G7 showed no significant variation 
in peripheral blood mononuclear cells (27). HLA-G1, -G2, 
-G5, and -G6 expression varied during embryonic maturation 
whereas HLA-G3 and -G4 displayed no variation in preimplan-
tation embryos during in vitro differentiation (28). In normal 
HBEC, HLA-G1 and -G5 transcripts are both expressed, with 
less HLA-G1 than HLA-G5 protein (14). Conversely, in lung 
cancer, the transcriptional level of HLA-G5 is lower than 
HLA-G1, with a higher overall HLA-G mRNA and protein 
isoform expression in tumor tissues compared to unaffected 
lung samples (29).
These data suggest that the bronchial epithelium may play a 
central role in pulmonary local immune responses via HLA-G 
expression, in an independent manner from pro-inflammatory 
cytokine regulation. HLA-G expression could also influence 
HBEC proliferative and differentiation abilities. A dysregulation 
of HLA-G isoforms in an asthma context could lead to both an 
impaired immunoregulatory capacity and altered epithelium 
differentiation properties.
TaBle 1 | Patient characteristics and their differences.
Patients’ characteristics healthy controls Ma sa p-Value
Number under study 15 16 16
Age (years) (medians and range) 46 (17–61) 60 (36–65) 59 (47–71) NS
Sex (% female) 80 71.4 57.1 NS
Control of asthma (%) NA 100 14 0.002
Exacerbations (number during last year) NA 14 100 0.002
Best FEV1 (% and predicted) 100 (100–122) 100 (76.4–109) 70 (60.4–85) 0.01
Blood eosinophils/mm3 (medians and range) 150 (130–200) 110 (36–190) 180 (40–1,290) NS
Allergy (%) 0 28.6 57.1 NS
Sinusitis (%) 40 71.4 85.7 NS
Bronchorrhea (%) 0 42.8 57.1 NS
GERD (%) 40 42.8 57.1 NS
Comorbid condition, ≥1 (%) 20 42.8 57.1 NS
ICS (%) NA 42.8 100 0.03
LAβ2 (%) NA 42.8 100 0.03
SAβ2 (%) NA 71.4 100 NS
OCS (%) NA 0 57.1 0.01
Differences between two groups were analyzed using the Mann–Whitney U test, and differences among the three groups were analyzed using the Kruskal–Wallis test, followed by a 
post hoc Bonferonni analysis. The χ2 test was used to evaluate dichotomous characteristics of patients.
NA, non-applicable; NS, non-significant.
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The main objectives of this study were to analyze HLA-G 
isoform expression in normal, severe, and mild asthmatic 
HBEC, during the HBEC re-differentiation process, and to 
investigate HLA-G regulation by a T2-related representative 
cytokine (IL-13) activation pathway. This study, performed on a 
rarely accessible method of HBEC derived from endobronchial 
biopsies fully re-differentiated into bronchial epithelium tissue 
using an air–liquid interface (ALI) culture, is the first to have 
investigated into the expression of all of the HLA-G mRNA 
isoforms.
MaTerials anD MeThODs
ali culture of human Bronchial epithelial 
cells
Healthy control (HC) subjects and patients with mild asthma 
(MA) and severe asthma (SA) were recruited after written 
informed consent at the Clinique des Bronches, Allergie et 
Sommeil, AP-HM Hôpital Nord, Marseille, France. The patients 
belonged to the Bronchial Obstruction and Asthma Cohort 
(COBRA—Cohorte Obstruction Bronchique et Asthme) sponsored 
by the French National Institute of Health and Medical Research, 
INSERM [IDRGB 2008-A00284-51, Afssaps 2008-0113]. Asthma 
diagnosis and severity classification were carried out as previously 
described (6). Patients’ characteristics are detailed in Table 1.
Human bronchial epithelium cells obtained from bronchial 
biopsy specimens were cultivated under ALI conditions, as previ-
ously described (6). Briefly, bronchial epithelial biopsy tissue was 
dissociated and suspended in bronchial epithelial growth medium 
(Lonza, Switzerland). After seeding in multiwell plates coated with 
a solution of fibronectin and collagen, cells were expanded in a 
flask and then plated on uncoated nucleopore membranes in a 1:1 
mixture of bronchial epithelial growth medium and Dulbecco’s 
modified Eagle medium (Life Technologies, France) applied on 
the basal side only to establish the ALI. Cells were maintained in 
culture for 21 days to obtain a differentiated cell population with 
a mucociliary phenotype.
cell line culture
Human choriocarcinoma cell line (JEG-3) was used as control 
for HLA-G expression. JEG-3 (HTB-36) cells were obtained 
from the American Type Culture Collection (LGC Standards, 
France). All reagents and culture media were provided by Life 
Technologies. JEG-3 cells were cultured in DMEM containing 
10% fetal bovine serum.
rna extraction and reverse Transcription
Expression studies according to asthmatic severity, re-differen-
tiation, and IL-13 stimulation were performed on HBEC RNA 
from 19 patients (HC N = 5, MA N = 7, SA N = 7) at day (D) 0, 
D7, D14, and D21, with and without IL-13 stimulation (5 and 
10 ng, 213-ILB/CF; R&D systems, France). HBEC total RNA was 
isolated using the RNeasy kit (Qiagen, France).
Total RNA from JEG-3, at 60% confluence after 24  h, was 
extracted from cell lysis using the mirVana™ PARIS™ Kit (Life 
Technologies).
cDNA was reverse transcripted using Superscript III Reverse 
Transcriptase (Life Technologies) following manufacturer’s 
recommendations.
real-time Pcr analyses
Real-time PCR analyses were performed using TaqMan technol-
ogy (Life Technologies) using nine primer/probe targeting: all 
HLA-G transcripts (ex1–2 and ex5–6), HLA-G1/4/5 (ex2–3), 
HLA-G1/5 (ex3–4), HLA-G2/6 (ex2–4), HLA-G3 (ex2–5), HLA-
G5/6 (int4–ex5), and ex8 14 bp ins/del polymorphism. All were 
designed by Acobiom (Montpellier, France) except pan HLA-G 
ex5–6 (Hs03045108_m1, Life Technologies) (Table S1 and 
Figure S1 in Supplementary Material). Actinβ (ACTB) was used 
as an endogenous control (normalizer) and CCL26 (eotaxin-3) 
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as an IL-13 stimulation control (ACTB Hs99999903_m1; CCL26 
Hs00171146_m1; Life Technologies).
Different plasmids were constructed to check specificities and 
efficiencies of primers/probes used for real-time PCR analyses. 
One ACTB and eight HLA-G amplicons were obtained from 
PCR performed on JEG-3 or HBEC cDNA using the Taq DNA 
Polymerase recombinant kit (Life Technologies) according to 
manufacturer’s protocol (Table S2 in Supplementary Material for 
plasmids characteristics). Purified PCR amplicons (NucleoSpin, 
Macherey-Nagel, France) were cloned in pGEM-T vectors 
(Promega, France) and One Shot TOP10 Competent Cells 
(Life Technologies) as previously described (30). Efficiencies of 
HLA-G and ACTB primer/probe were calculated using plasmid 
dilutions (first point at 106 copie numbers/μl and six points dilu-
tion 1:10), and checked in JEG-3 dilutions, according to MIQE 
Guidelines (31).
Real-time PCR mixture was performed in a total volume of 
20 µL, including 3 µL of cDNA or plasmid dilution, 1× TaqMan® 
Fast Universal PCR Master Mix no AmpErase® UNG (Life 
Technologies), 900  nM of each primer, and 200  nM of probe. 
StepOnePlus™ Real-Time PCR System (Life Technologies) was 
used to perform real-time PCR according to manufacturer’s 
recommendations (95°C for 20 s, followed by 40 cycles of 95°C 
for 1 s, and 60°C for 20 s). Each experiment was carried out in 
duplicate, including a negative control, a positive control, and 
appropriate plasmid dilutions.
Cycle threshold (Ct) data were determined with defined 
threshold settings [0.2 for ACTB and 0.1 for CCL26 (eotaxin-3) 
and HLA-G isoforms]. Average Ct was calculated with StepOne 
2.1 software (Life Technologies), excluding Ct duplicates with an 
SD higher than 0.5.
JEG-3 and an HBEC HC sample were respectively used as 
calibrators for HLA-G isoforms quantification and exon 8 14 bp 
ins/del. Each D0 sample from the re-differentiation experiment 
was used as a calibrator to quantify HLA-G isoforms from D7 to 
D21. Each unstimulated HBEC sample from the IL-13 stimula-
tion experiment (5 and 10 ng of IL-13) was used as a calibrator. 
ACTB was used as normalizer.
Quantification was carried out using the relative stand-
ard curve method with the following equation (32): Fold 
change = (E target) × ΔCt target/(E normalizer) × ΔCt normal-
izer, with, E = 10[−1/slope], efficiency calculated from standard curve 
(plasmid dilution), ΔCt target = Ct targetcalibrator − Ct targetsample 
and ΔCt normalizer = Ct normalizercalibrator − Ct normalizersample.
HLA-G isoforms ratio was calculated according Pan HLA-G 
ex5–6 expression using the following equation (33): Ratio 
Gx = 2−ΔCt Gx/2−ΔCt Pan HLA-G ex5–6 with Gx being the HLA-G isoform 
understudy.
hla-g Protein expression
The 4H84 antibody was used to confirm protein expression in 
HBEC. 4H84 is directed against a linear epitope of the unfolded 
α1 domain of the HLA-G free protein, which is present in 
all HLA-G isoforms (34, 35). Western blot analyses were 
performed on HBEC protein lysates at D21 (HC N =  10, MA 
N =  9, SA N =  9). Cells were rinsed with PBS and extracted 
in lysis buffer (50 mM Tris–HCl, pH 7.6, 150 mM NaCl, 1 mM 
EDTA, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 2 mM 
MgCl2) containing a protease inhibitor cocktail (Sigma-Aldrich, 
France). Samples were normalized for protein content with 
the BCA protein assay kit (Perbio Science, France). Protein 
samples (20  µg) were fractionated on a 4–15% SDS-PAGE, 
followed by a semi-dry transfer onto a PVDF membrane 
(Biorad, France). Blots were blocked with blotting buffer (5% 
non-fat milk, 10  mM Tris–HCl, 150  mM NaCl, 0.1% Tween 
20) before being probed with mouse monoclonal antibody 
against HLA-G (1:500) (clone 4H84; Perbio Science, France). 
Rabbit polyclonal antibody against glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (1:200) (clone 9545; Sigma-Aldrich) 
was use for standardization. Horseradish peroxidase-conjugated 
anti-mouse IgG (1:20,000, SantaCruz) were used as secondary 
probes. The densitometric analysis of immunoblots was per-
formed using Alphaview Software (ProteinSimple). Results are 
expressed as the ratio of HLA-G/GAPDH bands mean intensity 
(A.U., arbitrary unit).
hla-g allele Typing
Allele typing was carried out by PCR and direct sequencing from 
all HBEC cDNA using JEG-3 cDNA as control (G*01:01; G*01:01, 
exon8 14  bp ins/ins) (18). PCR amplification was performed 
using a Multiplex PCR Kit (Qiagen) following manufacturer’s 
recommendations with primers targeting HLA-G exon 1 to exon 
5 (Table S1 in Supplementary Material). Direct sequencing was 
performed using Big Dye Terminator V1.1 kit (Life Technologies) 
according to the manufacturer’s protocol. Alignments were per-
formed with Codon Code Aligner version 3.7.1 (Codon Code 
Corporation, USA) using HLA-G allele sequences from the 
official IMGT/HLA database 3.20.0 May 2015 (36).
statistical analyses
All association and correlation tests were performed with 
GRAPH PAD Prism 5 software (CA, USA, www.graphpad.com). 
Differences among patient characteristics were tested using 
Mann–Whitney t-test to test two modalities. Kruskal–Wallis 
one-way ANOVA followed by Dunn post hoc test was used to test 
more than two modalities.
mRNA expression fold change data are presented as median 
and range (min, max). Correlations between HLA-G isoforms at 
D0, D7, D14, and D21 for each clinical condition (HC, MA, and 
SA) were performed using Pearson’s chi-square test. HLA-G iso-
form data that displayed a significant correlation were cumulated 
in subsequent analyses. HLA-G isoform data that displayed no 
correlation were analyzed separately.
Associations and correlations between HLA-G isoform 
expression and clinical (allergy, asthma severity, eosinophil 
count), experimental (HBEC re-differentiation, IL-13 stimula-
tion), biological (age, gender), and genetic parameters were done 
using the Mann–Whitney t-test and Kruskal–Wallis one-way 
ANOVA. Pearson’s test was used for numerical correlation. To 
further investigate the effect of HLA-G alleles on HLA-G iso-
form mRNA expression, the comparison of a single observation 
to the mean of the sample has been used (37). In this particular 
case, data are represented as mean with SD. Repeated-measures 
one-way ANOVA was applied specifically to test the association 
FigUre 2 | ratios of isoform transcriptional expression analyzed by Q-Pcr. Isoform median ratios are compared to Pan HLA-G ex5–6 isoform expression 
in healthy controls (solid line), patients with mild asthma (dashed line), and patients with severe asthma (dashed and dotted line) at day 0 (D0), D7, D14, and D21. 
Medians with range are described in Table S4 in Supplementary Material.
FigUre 1 | hla-g isoform transcriptional expression analyzed by Q-Pcr. Median fold change as compared to JEG-3 in healthy controls (solid line), patients 
with mild asthma (dashed line), and patients with severe asthma (dashed and dotted line) at day 0 (D0), D7, D14, and D21. Medians with range are described in 
Table S3 in Supplementary Material.
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between HLA-G isoform mRNA expression and experimental 
parameters.
resUlTs
The characteristics of the individuals studied are shown in Table 1.
hla-g isoforms expression in hBec 
from hcs
All HLA-G mRNA isoforms were observed in re-differentiated 
HC epithelium at D21 except HLA-G3 (Table S3 in Supplementary 
Material). Compared to JEG-3, extensively analyzed for HLA-G 
expression, HBEC showed a lower expression of all HLA-G 
isoforms, except pan ex1–2 HLA-G (Figure 1).
HLA-G isoform ratios, calculated in comparison with 
pan HLA-G ex5–6, showed that HLA-G1/-G5 were the most 
expressed isoforms in HC [9.81 (0.25–12.26)] and in JEG-3 [2.8 
(2.10–16.11)] (Figure  2; Table S4 in Supplementary Material). 
It is noteworthy that HC displayed higher ratios for ex1–2 and 
HLA-G5/-G6 [5.23 (1.77–6.79) and 0.12 (0.03–1.38)] than JEG-3 
[0.21 (0.05–0.52) and 0.04 (0.009–0.32)].
hla-g isoform correlations
Correlation of expression was investigated for each pair of 
isoforms in asthmatic patients and controls. Expression of 
pan HLA-G ex5–6, HLA-G1/-G4/-G5, and HLA-G1/-G5, all 
displayed significant positive correlation at D21 for HC, MA, 
and SA (Figure S2 in Supplementary Material). Therefore, these 
FigUre 4 | hla-g protein expression in human bronchial epithelium 
cell lysates from healthy controls (hc), patients with mild asthma 
(Ma), and patients with severe asthma (sa). Semi-quantitative analysis 
(A.U., arbitrary units, mean and range) of Western Blot 4H84 staining 
normalized with GAPDH (mAb clone 9545) staining in HC [N = 10; 0.231 
(0.137–0.552)], MA [N = 9; 0.186 (0.06–0.291)] and SA [N = 9; 0165 
(0.004–0.492)]. The bands observed at 39 and 37 kDa may correspond to 
the biggest open reading frame from nucleotide 1 of HLA-G1 and HLA-G5 
mRNA, respectively. Kruskal–Wallis ANOVA (HC, MA, SA) p = 0.214, non- 
significant; Mann–Whitney (HC vs. MA and SA) p = 0.088, non-significant.
FigUre 3 | Transcriptional expression analyzed by Q-Pcr of 
cumulated hla-g1/-g4/-g5, hla-g1/-g5, and pan hla-g ex5–6 in 
human bronchial epithelium cells (hBec) on day 21. Fold change 
compared to JEG-3 in HBEC from healthy controls (HC) [0.156 (0.03–0.92)], 
patients with mild asthma (MA) [0.03 (0.0008–0.19)], and patients with severe 
asthma (SA) [0.06 (0.001–0.13)]. Kruskal–Wallis ANOVA performed on three 
modalities: p = 0.047. HC showed a significantly higher expression of 
cumulated pan-G1-G4-G5 than both MA and SA (p < 0.001 and p < 0.05, 
respectively; Mann–Whitney test).
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data were cumulated in association analyses and referred to as 
“cumulated pan-G1-G4-G5.”
Expression of ex1–2 of HLA-G displayed no correlation with 
any other HLA-G isoforms.
HLA-G2/-G6 showed a significant positive correlation with 
pan HLA-G ex5–6, HLA-G1/-G4/-G5, and HLA-G1/-G5 at 
D0 for HC and SA, but not for MA. HLA-G5/-G6 displayed 
a significant positive correlation with HLA-G1/-G4/-G5, HLA-
G1/-G5, and HLA-G2/-G6 at D0 for HC.
hBec Derived from asthmatic Patients 
Displayed lower hla-g expression and 
specific isoform ratios
HLA-G isoform expression and ratios displayed different patterns 
in fully re-differentiated HC, MA, and SA. At D21, HC showed 
a significantly higher expression of cumulated pan-G1-G4-G5 
than both MA and SA [Kruskal–Wallis ANOVA performed on 
three modalities: p = 0.047, Mann–Whitney performed on two 
modalities HC vs. MA p < 0.001 and HC vs. SA p < 0.05; HC: 
0.156 (0.03–0.92), MA: 0.03 (0.0008–0.19), SA: 0.06 (0.001–0.13); 
Figure 3].
At D21, SA displayed the highest ex1–2 (pan HLA-G) expres-
sion; however, this difference was not significant (Figure 1; Table 
S3 in Supplementary Material). Ex1–2 (pan HLA-G) showed 
the highest ratio compared to other isoforms for both MA [4.26 
(1.03–13.94)] and SA [14.35 (1.47–22.93)], whereas in HC the 
highest ratio was for HLA-G1/-G5 [9.81 (0.25–12.26)] compared 
to SA [5.18 (0.57–11.30)] and MA [0.50 (0.26–8.46)]. HLA-
G5/-G6 ratio in HC [0.12 (0.03–1.38)] was higher compared to 
MA [0.07 (0–3.07)], SA [0.04 (0.02–0.90)]. No difference was 
observed between HC, MA, and SA for HLA-G2/-G6. HLA-
G3 had the lowest ratio among HLA-G isoforms with even an 
absence of signal for some patients. At D21, only SA expressed 
this isoform.
Protein HLA-G expression was assessed in HC, MA, and 
SA. Alpha1 domain expression (4H84 antibody) was found 
to be non-significantly higher in HC compared to MA and SA 
[0.231 (0.137–0.552), 0.186 (0.06–0.291), 0.165 (0.004–0.492), 
respectively; Kruskal–Wallis ANOVA HC, MA, SA p =  0.214, 
non-significant; Mann–Whitney HC vs. MA and SA p = 0.088, 
non-significant; Figure 4; Table S5 and Figure S3 in Supplementary 
Material]. The bands observed at 39 and 37 kDa may correspond 
to the biggest open reading frame from nucleotide 1 of HLA-G1 
and HLA-G5 mRNA, respectively.
hBec Derived from sa Patients 
Display specific hla-g expression 
during re-Differentiation
Differences in HLA-G isoform ratios during HBEC re- 
differentiation from D0 to D21 were observed between HC, 
MA, and SA (Figure 2; Table S4 in Supplementary Material). 
HC maintained the highest HLA-G1/-G5 ratio from D7. In 
SA, ex1–2 (pan HLA-G) showed an increased ratio, whereas 
it was stable in HC and MA from D7. When compared to 
D0, HLA-G1/-G5 expression decreased significantly at D7, 
D14, and D21 for HC (p =  0.033) and MA (p =  0.013), but 
not for SA (p =  0.425) (Figure  5). HLA-G2/-G6 expression 
decreased significantly on D7, D14, and D21 for HC, MA, and 
SA (p < 0.0001) (Figure 5). At D0, HLA-G3 was expressed by 
some individuals in HC (N = 4), MA (N = 3), and SA (N = 6), 
but the expression was only maintained in SA at D21 (N = 2). 
FigUre 5 | Transcriptional expression analyzed by Q-Pcr of hla-g1/g5 and hla-g2/g6 in healthy controls (hc), patients with mild asthma (Ma), 
and patients with severe asthma (sa). Expression fold change during human bronchial epithelium cells re-differentiation is compared to D0. HLA-G1/-G5 
expression is significantly higher at D0 for HC and MA, but not for SA (Kruskal–Wallis ANOVA: p = 0.033, p = 0.013, and p = 0.425, respectively). HLA-G2/-G6 
expression was significantly lower at D0 for HC, MA, and SA (Kruskal–Wallis ANOVA: HC, MA, and SA p < 0.0001).
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No significant variation was observed during re-differentiation 
for the other HLA-G isoforms.
asthmatic Patients Display specific 
hla-g alleles
HLA-G*01:01 frequency was higher in HC (N = 10, Fq = 1) than 
both MA and SA (both N = 9, Fq = 0.64; χ2, p = 0.03). Asthmatic 
patients displayed HLA-G*01:04 (MA N = 2, Fq = 0.14; SA N = 1, 
Fq = 0.07) and HLA-G*01:06 (MA N = 3, Fq = 0.22; SA N = 4, 
Fq = 0.29). One MA patient carried an HLA-G*01:04 allele and 
an unreported allele (C/C at position 351 and C/T at position 800, 
respectively, excluded and included in the HLA-G*01:06 allele). 
HLA-G*01:06 allele frequency in MA and SA were significantly 
higher compared to healthy populations from South-East France 
(38) (χ2, respectively, p = 0.03 and p < 0.001). HC, MA, and SA 
showed equal frequencies for ex8 ins (HC N = 5, Fq = 0.50; both 
MA and SA N = 8, Fq = 0.57) and ex8 del.
hla-g expression and genetic 
Polymorphism
No significant difference was observed in HLA-G expression 
according to ex8 genotype. Ex8 del displayed a significant posi-
tive correlation with HLA-G1/-G4/-G5, HLA-G1/-G5, HLA-G3, 
and ex5–6 (pan HLA-G) at D21 in SA but not in HC and MA 
(Figure S2 in Supplementary Material). No correlation was 
observed between ex8 ins and any of the isoforms. Ex8 ins/del 
heterozygous individuals showed no correlation between both 
alleles expression.
Taking MA and SA together, cumulated pan-G1-G4-G5 
showed a non-significantly higher median expression in HLA-
G*01:04 individuals [0.53 (0.03–1.04)] than in HLA-G*01:01 
individuals [0.05 (0.01–0.18)] and HLA-G*01:06 individuals 
[0.04 (0.02–0.07)].
hla-g expression is not Modulated By 
il-13 stimulation
IL13 stimulation had no effect on HLA-G expression in any of the 
HBEC tested (Figure 6) or during the re-differentiation process 
(p = 0.419). IL-13 stimulation was, however, effective, as shown 
by CCL26 (eotaxin-3) expression, which was significantly higher 
in stimulated compared to unstimulated samples (p < 0.0001).
DiscUssiOn
Inflammation of the airways and dramatic bronchial epithelium 
structural remodeling are features of asthma. This disease 
includes various phenotypes which are unequally controlled by 
therapeutics, mostly based on the suppression of immune cell 
activation. Thus, attempts are made to find alternative therapies 
in order to manage non-responding patients, most of whom are 
severe asthmatic. Given that the immunotolerant HLA-G mol-
ecule is well-known for its implication in various inflammatory 
conditions, a more comprehensive analysis of its local bronchial 
expression in asthmatic patients could bring this molecule into 
the limelight as a new therapeutical strategy.
The main objectives of this study were to show that HLA-G 
isoform expression was impaired in an asthmatic context and to 
confirm that HLA-G isoform expression was not affected by a 
typical T2 cytokine, namely IL-13.
The present study is the first to have investigated into the 
expression of all of the HLA-G mRNA isoforms. All HLA-G iso-
forms were expressed in fully re-differentiated HBEC from HC, 
MA, and SA. HLA-G mRNA expression was significantly reduced 
FigUre 6 | hla-g1/g5 and ccl26 (eotaxin-3) expression fold change at D21 in human bronchial epithelium cells (hBec) stimulated with 5 and 
10 ng of il-13 from healthy controls, patients with mild asthma (Ma), and patients with severe asthma (sa) compared to unstimulated samples (Us). 
Kruskal–Wallis ANOVA performed on three modalities. IL13 stimulation had no effect on HLA-G expression in any of the HBEC tested. CCL26 (eotaxin-3) expression 
was significantly higher in stimulated compared to US (p < 0.001).
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in both MA and SA compared to HC. HLA-G mRNA expres-
sion was not affected by IL-13. Furthermore, genotyping results 
showed that both MA and SA displayed higher HLA-G*01:04 and 
*01:06 allelic frequencies.
No currently available commercial tools allow the quantifica-
tion of the different HLA-G protein isoforms, the 4H84 antibody 
recognizes all HLA-G isoforms. In our study, HLA-G mRNA 
isoform expression was investigated by the highly sensitive 
Real-time TaqMan® PCR technology in HBEC–ALI from both 
asthmatic patients and healthy donors. HBEC in ALI culture 
maintain morphological features and disease markers associated 
with mild and severe asthma (6). Most importantly, this ex vivo 
model allows epithelial analysis without any immune cells and 
cytokines known to influence HLA-G expression [for review, see 
Ref. (18)] and represents a most suitable model to investigate into 
the specific signature of normal and asthmatic HBEC HLA-G 
expression. Furthermore, ALI monoculture allows dynamic 
analysis of re-differentiation for 21 days.
We observed a significantly impaired HLA-G mRNA expres-
sion of cumulated pan-G1-G4-G5 in both MA and SA compared 
to HC in a fully re-differentiated epithelium. This lower expres-
sion could be associated to the specific allelic pattern displayed 
by asthmatic patients, as MA and SA showed a significantly lower 
frequency of HLA-G*01:01 compared to HC. HLA-G*01:06 allele 
was significantly higher in both MA and SA compared to the 
healthy population from South-East France (38). These results are 
in accordance with HLA-G being defined as a potential asthma 
susceptibility gene by fine-mapping and positional candidate 
study (11) and with previous studies showing a negative effect of 
HLA-G*01:04 and HLA-G*01:06 in bronchial epithelium patho-
logical situations (39). These alleles could have a negative influence 
on bronchial epithelium capability of resolving inflammation 
either because they code for a less functional protein or, more 
likely, because they express less protein. Whether these coding 
alleles are associated with an impaired protein or with differential 
quantitative expression needs to be further investigated; however, 
former studies have shown that HLA-G*01:04 and HLA-G*01:06 
are associated with specific SNPs in regulatory regions with an 
impact on their expression (38, 40).
The genotype ex8 ins/del did not have any effect on HLA-G 
mRNA expression in HC, MA, or SA, in agreement with Zheng 
et  al. who showed no relationship between ex8 ins/del status 
and sHLA-G plasma levels in allergic asthma in childhood (13). 
Former studies showed that the ex8 deletion confers a higher 
soluble/membrane-bound HLA-G expression ratio whereas the 
ex8 insertion is associated with higher degree of mRNA stabil-
ity, increased membrane-bound HLA-G expression, and more 
efficient inhibition of NK cytotoxicity (26). Here, we found that 
expression of isoforms bearing the ex8 deletion only correlated 
with cumulated pan-G1-G4-G5 in SA. Thus, SA might also dis-
play a lower HLA-G membrane/soluble ratio and a less efficient 
immune cell inhibition capacity than in MA and HC.
The influence of the other polymorphisms in regulatory 
regions, such as SNP −964 and +3,142 associated with asthma 
(11, 41), could not be explored here as genomic DNA was not 
available. SNPs in both 5′ UTR and 3′ UTR are in linkage dis-
equilibrium with coding alleles and are associated with HLA-G 
differential expression (38, 40), so they deserve to be addressed in 
a specific asthmatic cohort genetic study. Indeed, high resolution 
genetic analysis of both alleles and regulatory regions could shed 
some light on the HLA-G expression heterogeneity observed 
here.
Previous studies supported, however, a higher level of 
soluble HLA-G protein and local expression in asthmatic indi-
viduals compared to HCs (12, 13). Here, no significant difference 
between asthmatic patients and healthy individuals could be 
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distinguished by western blot analysis, and not all protein iso-
forms were observed. The quantity of translated protein may be 
too low to be detected by western blot, a hypothesis supported by 
Q-PCR isoforms ratio results, or these mRNA isoforms may not 
be translated, raising the question of their functional relevance. 
Furthermore, HLA-G mRNA and soluble protein expression are 
not always correlated, HLA-G expression can be highly hetero-
geneous according to cell type, and the proteins can be stored in 
the cytoplasm (28, 42). Some authors also hypothesized that at 
steady state, soluble HLA-G can be cleared from the organism 
at a certain rate and that some individuals can present higher 
soluble HLA-G blood levels although they produce a lower 
quantity of mRNA (26). Moreover, soluble HLA-G expression, 
not correlated to membrane-bound expression (43), can be 
expressed by different and/or distant cells from the bronchial 
epithelium (44).
MA and SA displayed specific alternatively spliced HLA-G 
isoform expression, correlation, and ratios; however, little is 
known about the exact function of these alternative isoforms. 
HLA-G2, -G4, and -G6 have been reported to display tolerogenic 
activity (20), and conflicting results have been reported concern-
ing HLA-G3, possibly due to chaperone proteins specific to the 
cell lines used (20, 24).
It is notable that the expression of exons 1 and 2, coding for 
the signal peptide, was higher in all HBEC than in JEG-3, SA 
displaying the highest ratio. Expression of exons 1 and 2 were 
not correlated with any of the other isoforms. No published data 
targeting exon 1 have also analyzed other exons (45) with which 
to confront our results. Differential expression of exons 1 and 2 
could specifically enhance HLA-E expression to resolve inflam-
mation; over-expression of HLA-E has been previously reported 
in tumor cells in colorectal cancer and was associated with the 
inhibition of NK or CD94+/NKG2A+/CD8+ T cells infiltrating 
tumor tissue (46).
HLA-G1/-G5 and HLA-G2/-G6 expression were the highest 
in undifferentiated HBEC, at D0, for HC, in accordance with 
HLA-G being expressed by undifferentiated cells as reported in 
mesenchymal stem cells (47). These results could support the 
involvement of HLA-G in epithelial proliferation and differentia-
tion potentials (16, 17).
SA displayed specific HLA-G isoform expression starting from 
the earlier stages of re-differentiation through to D21. Thus, both 
bronchial epithelium structural remodeling and impairment in 
inflammation resolution observed in asthma could be the result 
of HBEC intrinsic defects, embodied here by HLA-G isoform 
expression, rather than immune cell dysfunction.
The IL-13 activation pathway has been reported to act directly 
on airway epithelium inducing epithelial cell proliferation and 
differentiation (48). Here, IL-13 induced no modification of 
HLA-G isoform expression in any of the ALI cultures, extend-
ing the results of White et al. to asthmatic cells (14). Thus, even 
though IL-13 has a striking effect on airway epithelium, it does 
not affect HLA-G expression.
In conclusion, our study promotes HBEC in ALI culture as a 
suitable model for HLA-G expression analysis. We showed that 
HBEC obtained and cultivated in ALI from SA patients dis-
played a specific HLA-G isoform expression profile compared 
to those from MA and HC. Many mechanisms could lead to 
an impairment of HLA-G expression resulting from local 
asthmatic micro-environment specificities and subordinated by 
HLA-G genetic polymorphisms: transcriptional factors (18, 49), 
miRNA (41, 45, 50), epigenetic modifications (51), or splicing 
factors (52).
Whatever the inner processes of HLA-G regulation in HBEC, 
differential HLA-G isoform expression could be responsible for 
the loss of inflammation control and for epithelium structural 
remodeling in asthmatic patients. Therefore, this molecule might 
be an interesting alternative candidate to target for asthmatic 
patients not adequately responding to treatments focused on 
immune cell effectors. Many questions remain, however, in 
particular, deciphering the mechanism(s) responsible for differ-
ential HLA-G isoform expression, identifying the epithelial cell 
type(s) expressing HLA-G, and elucidating the function of each 
isoform and their actual receptor, if any, in the local bronchial 
micro-environment.
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TaBle s1 | Primer and probe characteristics used for hla-g allele typing 
(primers combination F1/r3, F2/r4, and F3r5) and for hla-g Q-Pcr 
analyses.
TaBle s2 | Plasmid characteristics used for hla-g Q-Pcr efficiency 
analyses.
TaBle s3 | Transcriptional hla-g expression analyzed by Q-Pcr. Median 
fold change with range compared to JEG-3 in healthy controls (HC), patients with 
mild asthma (MA), and patients with severe asthma (SA) at day 0 (D0), D7, D14, 
and D21, except for HLA-G Pan ex8 del calibrated with human bronchial epithelium 
cells HC.
TaBle s4 | Transcriptional hla-g analyzed by Q-Pcr. Isoform median and 
range ratios are compared to Pan HLA-G ex5–6 expression in healthy controls, 
patients with mild asthma (MA), and patients with severe asthma (SA) at day 0 
(D0), D7, D14, and D21. †Only one point available.
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